On the afternoon of the 19th, attendees are taking a commemorative photo at the '1st Bio Win-Win Exchange Meeting' held at GC Green Cross Mokam Town in Yongin-si, Gyeonggi Province. (Photo by Korea Pharmaceutical and Bio-Pharma Manufacturers Association)
[Asia Economy Reporter Chunhee Lee] The Korea Pharmaceutical and Bio-Pharma Manufacturers Association is continuously creating platforms for open innovation to promote research and development (R&D) activities across the industry, including AI-based new drugs and biopharmaceuticals.
On the afternoon of the 19th, the Pharmaceutical and Bio-Pharma Association announced on the 20th that it held the “1st Bio Win-Win Exchange Meeting” hosted by the Biopharmaceutical Committee at GC Green Cross Mokam Town in Yongin, Gyeonggi Province. About 150 representatives and R&D leaders from pharmaceutical and bio companies attended the event, which featured presentations on biopharmaceutical development topics and networking sessions lasting late into the evening.
In his welcoming remarks, Won Hee-mok, chairman of the Pharmaceutical and Bio-Pharma Association, emphasized, “The pharmaceutical and bio industry is characterized by a complex value chain involving everything from basic research to advanced technology fields,” adding, “Open innovation that breaks down the boundaries between industry, academia, and research institutes is no longer a choice but a necessity.”
At the event themed on the latest trends in biopharmaceutical technology, presenters shared key technologies and business strategies related to biopharmaceutical development. The presentations proceeded in the following order: ▲ Dual antibody platform development and successful technology export case with Sanofi (Sanghoon Lee, CEO of ABL Bio) ▲ Latest technology trends in Chinese Hamster Ovary (CHO) cell line development (Yeoncheol Kim, former LG Chem PhD) ▲ Development of culture processes for antibody production and key quality considerations (Yongho Ahn, Vice President of KNBS&Ecell) ▲ CMC development strategies and application cases for recombinant proteins (Jaehun Moon, Head of Platform Science & Technology Unit at GC Green Cross) ▲ Antibody drug separation and purification strategies (Jaehyun Kim, Executive Director at Cytiva) ▲ Importance of data-driven decision-making in biopharmaceutical development (Ikhyun Cho, Vice President of Protium Science) ▲ Recent trends and development cases of injectable devices for biopharmaceuticals (Jineon So, Research Fellow at LG Chem) ▲ Latest development trends and cases of allogeneic chimeric antigen receptor (CAR)-NK therapies for cancer treatment (Bokyung Min, Head of Cell Therapy Research Center at GC Cell).
After the presentations, the second part of the event featured free networking, allowing participants to communicate freely over dinner. A representative from a bio company who attended the event said, “It was a meaningful occasion to review the diverse technological status of major domestic biopharmaceutical development companies and exchange business cards directly,” adding, “I hope that various experts working in the pharmaceutical and bio industry will continue to actively interact and maintain lively communication.”
On the morning of the 19th, the "1st New Drug Development AI Platform Technology Briefing" is being held at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association building in Bangbae-dong, Seoul. (Photo by Korea Pharmaceutical and Bio-Pharma Manufacturers Association)
Meanwhile, on the same morning, the “1st New Drug Development AI Platform Technology Briefing” was live-streamed on YouTube from the association’s headquarters in Bangbae-dong, Seoul. Hosted by the AI New Drug Development Support Center, jointly established by the association and the Korea Health Industry Development Institute, about 130 participants including pharmaceutical and bio companies and AI startup representatives attended the event.
At the briefing on the theme of “AI-based Drug Discovery,” three AI startups?Medirita, Syntekabio, and Bioncite?each gave 40-minute presentations on AI platform technologies in drug development. Following the presentations, partnering sessions were held with pharmaceutical and bio companies interested in the technologies. The AI Center plans to continue providing opportunities for collaboration between pharmaceutical and bio companies and AI startups in new drug development by inviting AI technology companies again for the 2nd technology briefing scheduled for December.
The association will also hold a large-scale “KPBMA Open Innovation Plaza” event on December 5 to promote open innovation in the domestic pharmaceutical and bio industry and lead the achievement of tangible results. On that day, the association plans to announce the establishment of a “Pharmaceutical and Bio Technology Commercialization Promotion Platform.” The plan is to build a specialized, continuously shareable technology platform for the domestic pharmaceutical and bio industry to activate open innovation and produce visible outcomes.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
